A5024888979- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Liver Disease Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Hepatitis B Virus Studies
- Single-cell and spatial transcriptomics
- Colorectal Cancer Treatments and Studies
- Diet and metabolism studies
- Hormonal Regulation and Hypertension
- Systemic Lupus Erythematosus Research
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Respiratory viral infections research
- Influenza Virus Research Studies
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- interferon and immune responses
- Diabetes Treatment and Management
- Liver physiology and pathology
- Cytokine Signaling Pathways and Interactions
- Cancer Research and Treatments
- Lung Cancer Research Studies
- Immune cells in cancer
Johns Hopkins University
2022-2025
Sidney Kimmel Comprehensive Cancer Center
2022-2025
University of Maryland, Baltimore
2024-2025
University of Baltimore
2022-2024
Johns Hopkins Medicine
2024
Sidney Kimmel Cancer Center
2024
Johns Hopkins Hospital
2023
Convergence
2023
Bloomberg (United States)
2022
Temple University
2014-2022
Abstract Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 through the induction of tumor-specific immunity. We present results from single-arm, open-label, phase 1/2 study DNA plasmid PTCV (GNOS-PV02) encoding up 40 neoantigens coadministered with plasmid-encoded interleukin-12 plus pembrolizumab patients advanced HCC previously treated...
Objective Increased levels of type I interferon (IFN) and IFN–regulated genes are found in patients with systemic lupus erythematosus (SLE) may be central to its pathogenesis. Mitochondrial antiviral signaling protein (MAVS) is a key regulator IFN that undergoes dramatic prion‐like aggregation self propagates the activation signal from viral RNA amplify downstream production. We undertook this study determine whether such MAVS aggregates might play role sustained increased production SLE....
The treatment of hepatocellular carcinoma (HCC) has been transformed by the use immune checkpoint inhibitors. However, most patients with HCC do not benefit from immunotherapy. There is an urgent need to understand mechanisms that underlie response or resistance immunotherapy for HCC. syngeneic mouse models closely recapitulate heterogeneity human will provide opportunities examine complex interactions between cancer cells and nonmalignant in tumor microenvironment.
Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) the first-line setting or after sorafenib, but whether this treatment has efficacy prior anti-PD-(L)1 therapy unknown. We performed a multicenter retrospective review of advanced HCC treated ipilimumab plus nivolumab therapy, excluding anti-CTLA-4 treatment. Of 32 who met our inclusion criteria, regimens included atezolizumab bevacizumab (50%,
This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history HZ. Participants (stratified by age: 50–59, 60–69 70 y) received 2 doses HZ/su months apart were followed-up for another 12 months. Anti-glycoprotein E (gE) antibodies measured enzyme-linked immunosorbent assay before vaccination 1 month after...
633 Background: Immune checkpoint inhibitors (ICI) administered prior to liver resection (LR) lead pathological responses in patients with hepatocellular carcinoma (HCC). However, the relative value of versus radiological response predicting relapse-free survival (RFS) remains unclear. Methods: We pooled patient-level data from 111 (pts) HCC receiving ICI LR as part 5 phase I/II trials and observational clinical studies conducted 12 centres United States, Kingdom Asia, an academic consortium...
Background: Intrahepatic cholangiocarcinoma (iCCA) may be genomically subclassified by the presence of potentially actionable molecular aberrations, which pathogenic alterations in isocitrate dehydrogenase (IDH)1 and fibroblast growth factor receptor (FGFR)2 are most frequently observed. The impact these on tumor immune microenvironment remains incompletely understood. Methods: We performed a high-parameter spatial phenotyping iCCA samples with FGFR2 or IDH1 FGFR2/IDH1 wild-type controls at...
Abstract Most new cancer diagnoses occur in patients over the age of 65. The composition and function immune system changes with age, but how aged affects responses to checkpoint inhibitor (ICI) therapies remains incompletely understood. Here, using multiplex cytokine assay high-parameter mass cytometry, we analyze prospectively collected blood samples from 104 receiving ICIs. We find ( ≥ 65-years-old; n = 54) derive similar clinical outcomes as younger 50). However, aged, compared young,...
Neoadjuvant immunotherapy is thought to produce long-term remissions through induction of antitumor immune responses before removal the primary tumor. Tertiary lymphoid structures (TLS), germinal center-like that can arise within tumors, may contribute establishment immunological memory in this setting, but understanding their role remains limited. Here, we investigated contribution TLS immunity hepatocellular carcinoma (HCC) treated with neoadjuvant immunotherapy. We found induced formation...
506 Background: Neoadjuvant use of immune checkpoint inhibitors (ICI) is feasible and achieves pathological responses in a subset patients with hepatocellular carcinoma (HCC). However, it not clear whether response to ICI translates into long-term survival benefit. Methods: We analysed patient-level data from 86 subjects recruited 4 prospective phase I/II clinical trials prior liver resection (LR) 9 centres the United States, Europe, Asia included cohort 23 (pts) receiving neoadjuvant off...
4091 Background: Combination PD-(L)1/CTLA-4 blockade is approved in patients with advanced hepatocellular carcinoma (HCC) the first line or after treatment sorafenib, but it unclear if combination therapy has efficacy anti-PD-(L)1 alone a multikinase inhibitor. We evaluated responses to ipilimumab plus nivolumab HCC who previously received assess and safety of this regimen. Methods: performed multi-center retrospective review 18 years age older diagnosis based on histology imaging had at...
Please cite this paper as: Reisinger et al. Safety and tolerability of a 6‐week course oseltamivir prophylaxis for seasonal influenza in children. Influenza Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00367.x. In an open‐label study, 49 children aged 1–12 years received (30–75 mg once daily depending on bodyweight) 6 weeks prophylaxis. Seventeen participants reported 22 adverse events (AEs); three participants, AEs were considered probably drug related (nausea or vomiting). No...
Background: Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms that characterized by hormonal symptoms. While most PanNETs nonfunctional, there have been a few reported cases of patients with previously nonfunctional developing significant symptoms, indicating transformation into functional PanNET. Case Description: We describe two metastatic non-functional PanNET insulinoma. The clinical presentations were for severe symptomatic hypoglycemia symptoms seizures and loss...
Abstract Background: Tertiary lymphoid structures (TLS) are ectopic follicles that arise in non-lymphoid tissue. TLS may contribute to response immune checkpoint blockade (ICB) solid tumors, but understanding of the life cycle these structures, particularly circumstances their resolution and functional contribution this stage adaptive response, remains incomplete. Methods: We employed a multi-omics approach evaluate tumors patients with hepatocellular carcinoma (HCC) treated neoadjuvant ICB...
Abstract Background: In pancreatic ductal adenocarcinoma (PDAC), rare long-term survivors correlate with high intratumoral tertiary lymphoid structure (TLS) density. This finding prompted our investigation of clinically viable strategies to induce TLS in patients immune-excluded tumors. We previously reported the induction following administration a neoadjuvant GM-CSF-secreting allogeneic vaccine (GVAX) PDAC (NCT00727441). However, no clinical benefit was observed, likely owing immune...
Abstract Background: PD-1 inhibitors have modest efficacy as monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) tailored against neoantigens identified an individual’s tumor may enhance responses to through the induction of tumor-specific immunity. Here, we present results from a single-arm Phase Ib/2a trial evaluating DNA plasmid (GNOS-PV02) encoding up 40 co-administered with plasmid-encoded IL-12 (pIL12) combination pembrolizumab (PEMBRO)...
Abstract Neutrophils are integral to the metastatic tumor microenvironment (TME), and discrete subsets of neutrophils have been associated with pro- anti-tumor responses. However, composition in TME strategies harness for treatment disease remain poorly understood. Here, we studied role using mouse models pancreatic ductal adenocarcinoma (PDAC). By utilizing PDAC cells driven by mutant KRAS p53 controllable expression ovalbumin, an immunogenic antigen (“TumorAg ON” or “TumorAg OFF”), found...